The following is a summary of “Barriers and facilitators to sustaining a lupus patient decision aid in regular rheumatology ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Systemic lupus erythematosus, more commonly known as lupus, has a variety of symptoms and room for improvement when it comes ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Topical mupirocin helps reduce inflammation in lupus, offering a potential new approach for managing symptoms and improving ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.